Publication Date:
2013-05-03
Description:
We performed an integrated genomic, transcriptomic and proteomic characterization of 373 endometrial carcinomas using array- and sequencing-based technologies. Uterine serous tumours and approximately 25% of high-grade endometrioid tumours had extensive copy number alterations, few DNA methylation changes, low oestrogen receptor/progesterone receptor levels, and frequent TP53 mutations. Most endometrioid tumours had few copy number alterations or TP53 mutations, but frequent mutations in PTEN, CTNNB1, PIK3CA, ARID1A and KRAS and novel mutations in the SWI/SNF chromatin remodelling complex gene ARID5B. A subset of endometrioid tumours that we identified had a markedly increased transversion mutation frequency and newly identified hotspot mutations in POLE. Our results classified endometrial cancers into four categories: POLE ultramutated, microsatellite instability hypermutated, copy-number low, and copy-number high. Uterine serous carcinomas share genomic features with ovarian serous and basal-like breast carcinomas. We demonstrated that the genomic features of endometrial carcinomas permit a reclassification that may affect post-surgical adjuvant treatment for women with aggressive tumours.〈br /〉〈br /〉〈a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3704730/" target="_blank"〉〈img src="https://static.pubmed.gov/portal/portal3rc.fcgi/4089621/img/3977009" border="0"〉〈/a〉 〈a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3704730/" target="_blank"〉This paper as free author manuscript - peer-reviewed and accepted for publication〈/a〉〈br /〉〈br /〉〈span class="detail_caption"〉Notes: 〈/span〉Cancer Genome Atlas Research Network -- Kandoth, Cyriac -- Schultz, Nikolaus -- Cherniack, Andrew D -- Akbani, Rehan -- Liu, Yuexin -- Shen, Hui -- Robertson, A Gordon -- Pashtan, Itai -- Shen, Ronglai -- Benz, Christopher C -- Yau, Christina -- Laird, Peter W -- Ding, Li -- Zhang, Wei -- Mills, Gordon B -- Kucherlapati, Raju -- Mardis, Elaine R -- Levine, Douglas A -- 5U24CA143799-04/CA/NCI NIH HHS/ -- 5U24CA143835-04/CA/NCI NIH HHS/ -- 5U24CA143840-04/CA/NCI NIH HHS/ -- 5U24CA143843-04/CA/NCI NIH HHS/ -- 5U24CA143845-04/CA/NCI NIH HHS/ -- 5U24CA143848-04/CA/NCI NIH HHS/ -- 5U24CA143858-04/CA/NCI NIH HHS/ -- 5U24CA143866-04/CA/NCI NIH HHS/ -- 5U24CA143867-04/CA/NCI NIH HHS/ -- 5U24CA143882-04/CA/NCI NIH HHS/ -- 5U24CA143883-04/CA/NCI NIH HHS/ -- 5U24CA144025-04/CA/NCI NIH HHS/ -- P30 CA008748/CA/NCI NIH HHS/ -- P30 CA016086/CA/NCI NIH HHS/ -- P30 CA016672/CA/NCI NIH HHS/ -- P50 CA098258/CA/NCI NIH HHS/ -- U24 CA143799/CA/NCI NIH HHS/ -- U24 CA143835/CA/NCI NIH HHS/ -- U24 CA143840/CA/NCI NIH HHS/ -- U24 CA143843/CA/NCI NIH HHS/ -- U24 CA143845/CA/NCI NIH HHS/ -- U24 CA143848/CA/NCI NIH HHS/ -- U24 CA143858/CA/NCI NIH HHS/ -- U24 CA143866/CA/NCI NIH HHS/ -- U24 CA143867/CA/NCI NIH HHS/ -- U24 CA143882/CA/NCI NIH HHS/ -- U24 CA143883/CA/NCI NIH HHS/ -- U24 CA144025/CA/NCI NIH HHS/ -- U54 HG003067/HG/NHGRI NIH HHS/ -- U54 HG003079/HG/NHGRI NIH HHS/ -- U54 HG003273/HG/NHGRI NIH HHS/ -- U54HG003067-11/HG/NHGRI NIH HHS/ -- U54HG003079-10/HG/NHGRI NIH HHS/ -- U54HG003273-10/HG/NHGRI NIH HHS/ -- England -- Nature. 2013 May 2;497(7447):67-73. doi: 10.1038/nature12113.〈br /〉〈span class="detail_caption"〉Record origin:〈/span〉 〈a href="http://www.ncbi.nlm.nih.gov/pubmed/23636398" target="_blank"〉PubMed〈/a〉
Keywords:
Breast Neoplasms/genetics
;
Chromosome Aberrations
;
DNA Copy Number Variations/genetics
;
DNA Mutational Analysis
;
DNA Polymerase II/genetics
;
DNA-Binding Proteins/genetics
;
Endometrial Neoplasms/*classification/*genetics
;
Exome/genetics
;
Female
;
Gene Expression Regulation, Neoplastic
;
Genome, Human/*genetics
;
Genomics
;
Humans
;
Ovarian Neoplasms/genetics
;
Signal Transduction
;
Transcription Factors/genetics
Print ISSN:
0028-0836
Electronic ISSN:
1476-4687
Topics:
Biology
,
Chemistry and Pharmacology
,
Medicine
,
Natural Sciences in General
,
Physics
Permalink
